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Background: Neuropathic pain (NP) continues to be challenging to treat due to lack of effective drugs. Accumulating
evidence elucidated that glia-mediated inflammatory reactions play a pivotal role in the introduction and development
of NP. Besides, activation of the c-Jun N-terminal kinase (JNK)/monocyte chemoattractant protein-1 (MCP-1) pathway in
astrocytes has been reported to be critical for spinal astrocytic activation and neuropathic pain development after spinal
nerve ligation (SNL). Tanshinone IIA, a major active component of a traditional Chinese drug, Danshen, possesses potent
immuno-suppressive activities. The present study was undertaken to assess whether intraperitoneal administration of
tanshinone IIA sulfonate (TIIAS) has analgesic effect on SNL-induced neuropathic pain and whether the inhibition of
astrocytic activation and JNK/MCP-1 pathway is involved in the analgesic effect of TIIAS.
Methods: The effects of TIIAS on SNL-induced mechanical allodynia were assessed by behavioral testing.
Immunofluorescence histochemical staining was used to detect changes of spinal astrocytes and spinal pJNK
expression and localization. Immunofluorescence histochemistry and Western blot analysis were used to quantify
the SNL-induced spinal pJNK expression after TIIAS administration. Enzyme-linked immunosorbent assay (ELISA)
was used to detect the SNL-induced spinal expression of pro-inflammatory cytokines and MCP-1.
Results: Our results indicated that intraperitoneal TIIAS up-regulated the mechanical paw withdrawal threshold
(PWT) of NP, while astrocytic activation was suppressed and accompanied by the down-regulation of IL-1β and
TNF-α expression, as well as JNK phosphorylation in the spinal dorsal horn. Additionally, the release of MCP-1 was
dose dependently decreased. After co-treatment with TIIAS and JNK inhibitor (SP600125), no significant increases
in mechanical PWT and MCP-1 expression were observed compared with the TIIAS-treated group.
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Conclusions: The present results suggest that the analgesic effects of TIIAS in neuropathic pain are mainly mediated
by the down-regulation of SNL-induced astrocytic activation, which is via the inhibition of JNK/MCP-1 pathway.
Keywords: Astrocytes, MCP-1, Neuropathic pain, Tanshinone IIA sulfonate, AnalgesicBackground
Neuropathic pain (NP) is a devastating disease that affects
millions of people worldwide [1-4]. Many drugs have been
applied in the clinic such as tricyclic anti-depressants,
anti-epileptics, and opioids but fail to provide adequately
pain relief accompany with unacceptable side effects [3-5].
Hence, it is important to find alternative therapies for the
treatment of NP. However, the cellular and molecular
mechanisms underlying NP have yet to be fully elucidated.
In recent years, substantial evidence has shown that glial
cells play an important role in the generation and main-
tenance of NP [6-8]. Activated glial cells produce numer-
ous mediators such as pro-inflammatory cytokines and
growth factors that enhance neuronal activity. Previous
studies have suggested that microglia is critical for the ini-
tiation of NP, while astrocytes are mainly responsible for
the maintenance of NP. During the early stages of NP,
microglia in the spinal cord dorsal horn is activated by the
central terminals of primary sensory neurons [9-11]. How-
ever, activation of astrocytes is crucial for the maintenance
of pain. Recently, it has been demonstrated that c-Jun-N-
terminal kinase (JNK), a member of the mitogen-activated
protein kinase (MAPK) pathway, is expressed predomin-
ately by astrocytes and rapidly phosphorylated once the
astrocyte is activated [12,13]. Activated astrocytes then se-
crete numerous neuromodulators, sensitizing the neuronal
cell bodies and may, in the long term, bring about plastic
changes [14].
Danshen, a well-known traditional Chinese herbal medi-
cine derived from the dry roots of Salvia miltiorrhiza
Bunge, has a long history in treating cardiovascular and
cerebrovascular diseases in China [15,16]. Tanshinone IIA
(TIIA) (chemical structure shown in Figure 1A), one of
the major active components of Danshen extracts, has
been found to have anti-inflammatory, anti-oxidative, and
anti-apoptotic properties [17-19]. Moreover, our previous
studies indicated that tanshinone IIA sulfonate (TIIAS)
administration alleviated complete Freund’s adjuvant
(CFA)-induced inflammation and inflammatory pain [20],
suggesting that TIIAS is a promising anti-inflammatory
and anti-nociceptive drug. However, whether TIIAS pro-
duces protective effects to alleviate NP is not clear yet,
and the underlying mechanisms of anti-nociceptive effects
of TIIAS on NP are also need to be explored.
In the present study, utilizing the spinal nerve ligation
(SNL) pain model, we evaluated the possible anti-
nociceptive effects of TIIAS and its effects on astrocyticactivation. Considering the evidence for the inhibitory
effects of TIIAS on inflammatory action and the JNK
pathway, we also investigated the expressions of several
pro-inflammatory cytokines as well as monocyte chemo-
attractant protein-1 (MCP-1) after TIIAS administration.
Specific JNK inhibitor was also administrated to clarify
the possible mechanisms underlying the anti-nociceptive
effects of TIIAS.Methods
Animal and experimental design
Male Sprague–Dawley rats (220 to 250 g) were housed in
a temperature-controlled room in plastic cages (6 animals
per cage) with free access to food and water at 22°C to
25°C on a 12-h light/dark cycle. All of the experiments
reported in this study were conducted according to an
experimental protocol approved by the Animal Use and
Care Committee for Research and Education of The
Fourth Military Medical University (Xi’an, China). All
efforts were made to minimize the animals’ suffering
and the number of animals used [21].
The experimental design was as follows: Firstly, to verify
the analgesic effects of TIIAS in neuropathic pain and ex-
plore the related mechanisms, 144 rats were divided into 6
groups in the experiments: sham-vehicle group, sham-
TIIAS (50 mg/kg) group, sham-vehicle group, SNL-TIIAS
(2 mg/kg) group, SNL-TIIAS (10 mg/kg) group, and
SNL-TIIAS (50 mg/kg) group (n = 24 in each group). In
each group, 12 rats were used for the tests of mechanical
hypersensitivity and the other 12 rats were used for
immunofluorescence, Western blot, and enzyme-linked
immunosorbent assay (ELISA), 4 rats respectively. Sec-
ondly, to assess whether the intraperitoneal administration
of TIIAS influenced motor function, another 24 rats were
divided into 4 groups for rotarod test: naïve group, TIIAS
(2 mg/kg) group, TIIAS (10 mg/kg) group, and TIIAS
(50 mg/kg) group (n = 6 in each group). Thirdly, to further
verify the role of JNK in the analgesic effects of TIIAS,
specific JNK inhibitor (SP600125) was administrated and
another 80 rats were divided into 5 groups: sham group,
SNL-vehicle group, SNL-TIIAS (ED50) group, SNL-
SP600125 group, and SNL-TIIAS (ED50)-SP600125 group
(n = 16 in each group). In each group, 12 rats were used
for the test of mechanical hypersensitivity and the other 4
rats were used for ELISA test of MCP-1 expression on
post-operative day (POD) 10 of SNL injury.
Figure 1 Chemical structure of tanshinone IIA (TIIA) (A) and detailed timeline of the experiments (B). POD, post-operative day; SNL, spinal
nerve ligation; TIIA, tanshinone IIA; Veh, vehicle; IHC, immunohistochemistry; WB, Western blot; ELISA, enzyme-linked immunosorbent assay.
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SNL was performed according to our previous protocols
[22,23]. Briefly, rats were anesthetised with chloral hydrate
(300 mg/kg, i.p.). A midline incision was then made at the
L3 to S2 level, and the dorsal vertebral column from L4 to
S2 was exposed. After a portion of the L6 transverse
process was carefully removed, the left L5 spinal nerve
was carefully isolated and tightly ligated distal to the
dorsal root ganglion (DRG) with 6–0 silk thread. Sham-
operated animals were subjected to a similar surgical
procedure in which the isolated spinal nerves were not
ligated.
Drug administration
TIIAS (99% purity) was purchased from the National In-
stitute for the Control of Pharmaceutical and Biological
Products (NICPBP; Beijing, China). TIIAS was dissolved
in physiological saline for the in vivo experiments. And
the doses for the intraperitoneal administration of TIIAS
(three different doses: 2, 10, and 50 mg/kg, i.p.) wereselected according to previous studies [19,20]. Consider-
ing that astrocytes are activated from POD 3 of SNL,
TIIAS or saline was administrated intraperitoneally
30 min prior to behavioral experiments from POD 3 to
POD 10 once a day. To further verify the role of JNK in
the analgesic effects of TIIAS, a specific JNK inhibitor
SP600125 (5 μg/rat, in 5 ul normal saline containing 1%
DMSO) or vehicle (normal saline containing 1% DMSO)
was intrathecally administrated 15 min prior to the
measurement of mechanical pain behaviors from POD 3
to POD 10 after SNL. Intrathecal implantation was
performed by inserting polyethylene (PE) tubing to inject
the drug directly into the subarachnoid space of the
lumbar enlargement. After surgery, the neurologically
normal rats were injected with 2% lidocaine (10 μl)
through the intrathecal catheter to confirm whether the
PE tubing was in the intrathecal space. Only the rats
showing complete paralysis of both hind legs and tail
after administration of lidocaine were used for the
subsequent experiments. At the end of each experiment,
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the lumbar enlargement was verified visually by exposing
the lumbar spinal cord. Data from rats with incorrect PE
tubing position were abandoned from the study.
Rotarod testing
Motor dysfunction can have evident effects on nociceptive
behavioral tests [24]. To assess whether the intraperitoneal
administration of TIIAS influenced motor function, an-
other 24 rats were used in rotarod tests via an accelerating
rotating rod (Ugo Basile 7650, Varese, Italy). After 1 min
of training, rats were placed on the rotarod, which was
linearly accelerated from 4 to 40 rpm over 5 min. The
elapsed time before the rat fell on each of the three runs
with 10-min intervals between runs was recorded for each
rat. The test was repeated 30 min after the intraperitoneal
administration of TIIAS or saline once per day for 7 days,
and the time that the rat remained on the rotarod was
recorded. Final results are expressed as a percentage of
baseline value of each rat.
Mechanical hypersensitivity
Rats were placed on an elevated mesh grid that com-
pletely exposed the middle of the hind paw. Mechanical
hypersensitivity was tested using von Frey filaments
(Stoelting, Kiel, WI, USA) by experimenters who were
blinded to group assignment as described previously
[25]. The stiffness of the von Frey filaments was 2, 4, 6,
8, 10, 15, and 26 g. The hind paw was pressed with each
filament, in order of increasing stiffness, for 5 s. Rapid
pulling back, biting, or shaking of the hind limb within
5 s of the hind limb being pricked by one of the von
Frey filaments was taken as a positive sign of withdrawal.
The interval between trials was at least 5 min. For each
trial, the same hind limb was stimulated ten times by a
single von Frey filament before being stimulated by the
next larger filament. The minimal value that resulted in
at least six responses to ten stimulations was recorded
as the paw withdrawal thresholds (PWTs). The formula
for calculating the percentage change was 100–100 ×
(baseline of SNL-TIIAS − post-SNL-TIIAS)/(baseline of
SNL-vehicle − post-SNL-TIIAS).
Immunofluorescence
The rats were deeply anesthetised by injection of pento-
barbital (60 mg/kg, i.p.) and transcardially perfused with
200 ml of 5 mM sodium phosphate-buffered 0.9% (w/v)
saline (PBS; pH 7.3), followed by 500 ml of 4% (w/v)
paraformaldehyde in 0.1 M phosphate buffer (PB;
pH 7.4). The L5 spinal cord segments were harvested
and immersed in 30% (w/v) sucrose in 0.1 M PB over-
night at 4°C. Transverse spinal sections (25-μm thick-
ness) were then cut on a cryostat (Leica CM1800;
Heidelberg, Germany). After been rinsed in PBS (pH 7.2to 7.4) 3 times (10 min each), the sections were incu-
bated for 2 h at room temperature and then for 48 h at
4°C with anti-glial fibrillary acidic protein (GFAP) mouse
IgG (1:5,000; Chemicon, Temecula, CA, USA) or anti-
GFAP mouse IgG (1:5,000; Millipore, Billerica, MA,
USA) mixed with anti-pJNK rabbit IgG (1:100; Cell Sig-
nalling, Danvers, MA, USA) in PBS containing 0.3% (v/v)
Triton X-100, 0.25% (w/v) λ-carrageenan and 5% (v/v)
donkey serum (PBS-XCD). After being washed three times
in 0.01 M PBS (10 min each), the sections were incubated
for 4 h at room temperature with Alexa 594-conjugated
donkey anti-mouse IgG (1:500; Millipore, Billerica, MA,
USA) or a mixture of Alexa 488-conjugated donkey anti-
rabbit IgG and Alexa 594-conjugated donkey anti-mouse
IgG. After staining, all of the sections were mounted onto
glass slides and cover-slipped with 50% (v/v) glycerol and
2.5% (w/v) triethylenediamine (anti-fading agent) in
0.05 M PBS. Using a confocal laser-scanning microscope
(FV1000; Olympus, Tokyo, Japan), the sections were ob-
served with the appropriate laser beams and filter settings
for green-emitting Alexa 488 (excitation 488 nm; emission
530 nm) or red-emitting Alexa 594 (excitation, 543 nm;
emission, 590 to 615 nm). The digital images were cap-
tured using FV10-ASW-1.6 software (Olympus, Tokyo,
Japan), modified (15% to 20% contrast enhancement) in
Photoshop CS4 (Adobe Systems, San Jose, CA, USA) and
then saved as TIFF files.
Western blot analysis
Animals were deeply anesthetised by injection of pento-
barbital (60 mg/kg, i.p.) and then rapidly sacrificed. The
L5 spinal cord segments were dissected on ice according
to the termination of the L4 and L5 dorsal roots. The
left dorsal part of spinal cord was further split and then
homogenized with a hand-held pestle in sodium dodecyl
sulphate (SDS) sample buffer (10 ml/mg tissue) contain-
ing a mixture of proteinase and phosphatase inhibitors
(Sigma-Aldrich, St. Louis, MO, USA). The protein con-
centrations were estimated using the bicinchoninic acid
(BCA) method. The samples were heated in boiling
water for 8 min, loaded onto 10% SDS-polyacrylamide
gels (Bio-Rad Laboratories, Hercules, CA, USA) and
transferred to polyvinylidene difluoride membranes
(PVDF; Immobilon-P, Millipore, Billerica, MA, USA).
Membranes were blocked in a 5% BSA solution for 2 h
and probed with the following primary antibodies over-
night at 4°C: anti-GFAP mouse IgG (1:5,000; Chemicon,
Temecula, CA, USA), anti-pJNK rabbit IgG (1:300; Cell
Signalling, Danvers, MA, USA), anti-JNK rabbit IgG
(1:300; Cell Signalling, Danvers, MA, USA), and anti-β-
actin mouse IgG (1:3,000, Sigma-Aldrich, St. Louis, MO,
USA). The membranes were then incubated with the
following secondary antibodies for 2 h: horseradish perox-
idase (HRP)-conjugated donkey anti-rabbit IgG (1:5000;
Figure 2 The effects of intraperitoneal administered tanshinone
IIA sulfonate (TIIAS) on motor performance of normal rats in the
rotarod test. Compared with the baseline response, intraperitoneal
administration of TIIAS (2, 10, or 50 mg/kg) for 10 days did not affect
motor performance. The results were expressed as a percentage of
each rat’s own baseline value. TIIAS, tanshinone IIA sulfonate.
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anti-mouse IgG (1:5,000; Zhongshan, Beijing, China). The
membranes were rinsed three times (10 min each) with
Tris-buffered saline with Tween-20 (TBST) between each
step. All reactions were detected by the enhanced chemi-
luminescence (ECL) detection method (Amersham
Corporation, Arlington Heights, IL, USA). Restore Western
blot stripping buffer (Pierce Biotechnology, Inc., Rockford,
IL, USA) was used to detect the different proteins with
close molecular weight in the same PVDF membranes.
Briefly, after the antibodies for detecting pJNK were
stripped, the same PVDF membrane was used for the
detection of β-actin. The detailed steps were carried out
according to the manufacturer’s instructions. The densities
of protein blots were analyzed using Labworks Software
(Ultra-Violet Products, Cambridge, UK). The densities of
target proteins and β-actin immunoreactive bands were
quantified with background subtraction. The same size of
square was drawn around each band to measure the
density, and the background near that band was subtracted.
Target protein levels were normalized against β-actin levels
and expressed as relative fold changes compared to the
sham-vehicle group. The intensity of blots was quantified
with densitometry by the persons who were blinded to the
treatments.
Enzyme-linked immunosorbent assay
The left dorsal horns of the L5 spinal segments of animals
in different groups were split according to the same
method used for Western blot analysis. Spinal cord tissues
were homogenized in a lysis buffer containing protease
and phosphatase inhibitors. The amounts of IL-6, TNF-α,
IL-1β, and MCP-1 were measured by enzyme-linked im-
munosorbent assays using corresponding ELISA kits
(R&D Systems, Minneapolis, MN, USA).
Quantification and statistical analysis
Statistical analysis
All data were collected and analyzed by researchers
blinded to the surgery and reagents that were used. Re-
peated measures of ANOVA (with Bonferroni confidence
interval adjustment) tests were conducted for the data
from the rotarod and von Frey experiments. Data from
the Western blot and ELISA tests were analyzed using a
one-way ANOVA followed by least significant difference
(LSD) for post hoc analysis. All of the data are presented
as mean ± SEM, and all statistical analysis was performed
using SPSS software version 16.0 (SPSS Inc., Chicago, IL,
USA). A P value of <0.05 was considered statistically
significant.
Dose-effect curve and ED50 calculation
The TIIAS dosages were transformed into logarithm
dose with Prism, and the non-line fit was performed soas to build the dose-effect curve. Based on the dose-effect
curve, the ED50 of the effects of TIIAS on analgesia was
calculated. The reliability of the ED50 calculated from a
specific dose-effect curve was evaluated using the slope
factor generated by the GraphPad Prism version 5.01 for
Windows (San Diego, CA, USA, www.graphpad.com).
Results
Effects of intraperitoneal administration of TIIAS on
rotarod test
Motor dysfunction can have evident effects on nocicep-
tive behavioral results, and as such, it is essential to
assess whether the dosages of TIIAS in the present study
(2, 10, and 50 mg/kg) could induce impairment of motor
functions. To determine this, a rotarod test was carried
out to assess the influence of TIIAS administration on
motor function. As shown in Figure 2, there was no
difference in the performance of the rats in the vehicle
control group or in the TIIAS treatment (2, 10, and
50 mg/kg) group, indicating that intraperitoneal admin-
istration of TIIAS did not have an obvious measurable
effect on motor functions.
Intraperitoneal administration of TIIAS attenuated SNL-
induced mechanical hypersensitivity in a dose-dependent
manner
Next, we assessed whether TIIAS had effects on prevent-
ing mechanical hypersensitivity in the neuropathic pain
model of SNL. SNL injury resulted in prominent mech-
anical hypersensitivity as demonstrated in the SNL-
vehicle group (Figure 3A). Compared with that of the
SNL-vehicle group, intraperitoneal injection of 2 mg/kg
TIIAS did not influence PWT. However, TIIAS (10 and
Figure 3 The effects of intraperitoneal TIIAS on the SNL-induced mechanical allodynia. SNL injury resulted in prominent mechanical
allodynia. Intraperitoneal injection of TIIAS did not affect the pain threshold of the sham-operated group. Intraperitoneal administration of TIIAS
(10 or 50 mg/kg, from days 3 to 10, once a day) significantly reduced SNL-induced mechanical allodynia in a dose-dependent manner, whereas
2 mg/kg TIIAS did not change SNL-induced mechanical allodynia (A). *P < 0.05, compared with that of the SNL-vehicle group. #P < 0.05, compared with
that of the SNL-TIIAS (10 mg/kg) group. The dose-effect or log (dose)-effect curves for analgesic effects of TIIAS were shown in (B) and (C), n= 12 for
each group. SNL, spinal nerve ligation; TIIAS, tanshinone IIA sulfonate; Veh, vehicle.
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ical allodynia of ipsilateral hind paws from POD 3 to
POD 10 (P < 0.05, compared with that of the SNL-
vehicle group, respectively; Figure 3A). Furthermore, sig-
nificant differences in PWT were found between the two
groups treated with different dosages. TIIAS treatment
did not change the basal threshold in the sham-operated
group (Figure 3A). These results showed that the
anti-allodynia effects of TIIAS appeared to be dose-
related. Moreover, the effect of TIIAS on SNL-induced
mechanical allodynia was calculated based on the log
(dose)-response curve (Figure 3B). To calculate the slope
factor and ED50, we also calculated from the dose–
response curve (Figure 3C). The ED50 of TIIAS on SNL-
induced mechanical allodynia was 11.23 mg/kg, and theslope factor was 1.556, suggesting that our regimen for
dosage selection was robust.
TIIAS inhibits SNL-induced elevated astrocytic activation
In order to verify whether the anti-allodynic and anti-
hyperalgesic effects of TIIAS are accompanied with the
inhibition of astrocytic activation, we investigated GFAP
expression at POD 10 among the groups. Immunohisto-
chemical data showed that SNL injury induced GFAP
expression in the ipsilateral spinal dorsal horn on POD
10 compared with sham controls (Figure 4A). The
activated astrocytes by SNL injury also revealed hyper-
trophied cell bodies and thickened processes. SNL-
induced GFAP expression was also verified by Western
blot (P < 0.05, compared with that of the sham-vehicle
Figure 4 The effects of intraperitoneal injection of TIIAS on
SNL-induced spinal astrocytic activation and glial fibrillary
acidic protein (GFAP) expression. (A) SNL induced a remarkable
astrocytic activation indicated by GFAP up-regulation in the
ipsilateral spinal dorsal horn. The cell bodies of activated astrocytes
appeared hypertrophied, and the processes were thickened.
Intraperitoneal TIIAS administration inhibited the immunodensities of
GFAP in the ipsilateral spinal dorsal horn after SNL. Scale bar for a-f,
100 μm; scale bar (a’ and c’), 20 μm. (B) In accordance with the
immunofluorescence results, the Western blot analysis of GFAP
showed that SNL-induced GFAP up-regulation was suppressed by
intraperitoneal administration of TIIAS in a dose-dependent manner.
(C) Statistical analysis of the GFAP expressions after different treatments.
Asterisk or number sign each indicates statistically significant difference
with P< 0.05 between groups, n= 4 for each group. SNL, spinal nerve
ligation; TIIAS, tanshinone IIA sulfonate; Veh, vehicle; GFAP, glial fibrillary
acidic protein.
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istration of TIIAS resulted in a decrease in GFAP
immunofluorescence in the dorsal horn. Astrocytes in
the SNL-TIIAS group were not activated, similar to thesham-vehicle group. Western blot results (Figure 4B,C) also
verified that the expression of GFAP was significantly atten-
uated with 10 and 50 mg/kg TIIAS treatment (P < 0.05).Astrocytic JNK activation was dose dependently
decreased by administration of TIIAS
We further investigated the activation of astrocytic JNK
after TIIAS treatment. Immunohistochemical data
showed that almost all pJNK-positive cells were also
GFAP-positive astrocytes (Figure 5A). Additionally, the
effect of intraperitoneal administration of TIIAS on JNK
phosphorylation was tested. Western blot results showed
that after SNL, the expression of pJNK in spinal dorsal
horn of the SNL-vehicle group was significantly en-
hanced compared with that of the sham-vehicle group
(P < 0.05; Figure 5B,C), while intraperitoneal TIIAS
(50 mg/kg, the maximum dose in our studies) did not
affect pJNK expression in sham-operated rats compared
with that of the sham-vehicle group. Further analysis
showed that intraperitoneal administration of TIIAS
(2 mg/kg) did not obviously affect pJNK expression com-
pared with the SNL-vehicle group (P > 0.05; Figure 5B,C).
However, the expression of pJNK was significantly
attenuated compared with the SNL-vehicle group by
intraperitoneal TIIAS (10 and 50 mg/kg) administration
(P < 0.05; Figure 5B,C). Additionally, intraperitoneal
50 mg/kg TIIAS showed stronger effects on pJNK ex-
pression compared with the SNL-TIIAS (10 mg/kg)
group (P < 0.05; Figure 5B,C). These results suggest that
intraperitoneal TIIAS can effectively inhibit pJNK up-
regulation in a dose-dependent manner.
TIIAS attenuates SNL-induced up-regulation of pro-
inflammatory cytokines and MCP-1
In order to evaluate the possible signal transduction
pathways by which TIIAS alleviated SNL-induced hyper-
algesia, the effect of intraperitoneal administration of
TIIAS on the levels of pro-inflammatory cytokines such
as IL-1β, IL-6, and TNF-α as well as the chemokine
MCP-1 were investigated. Administration of TIIAS did
not change spinal pro-inflammatory cytokine expression
in sham-vehicle rats (Figure 6). However, SNL resulted
in significantly increased pro-inflammatory cytokine ex-
pression in the ipsilateral spinal dorsal horn on POD 10
(P < 0.05, respectively, compared with each of the sham-
vehicle; Figure 6A1,A2,A3). Our results demonstrated
that TIIAS administration inhibited the increased
expression of pro-inflammatory cytokines due to SNL.
The low dosage of TIIAS (2 mg/kg) could depress TNF-α
expression after SNL injury. However, this dosage did not
have any obvious effect on the expression of IL-1β and
IL-6 after SNL injury. In the higher dosage group (10
and 50 mg/kg), TIIAS could inhibit the increase of
Figure 5 The effects of intraperitoneal injection of TIIAS on
SNL-induced pJNK expression. (A) High-magnification images
demonstrated pJNK (green) was predominantly colocalized with GFAP
(red) as shown by overlapped staining (rightmost panel, yellow). Scale
bar, 20 μm. (B, C)Western blot analysis of pJNK showed that pJNK
expression increased in the ipsilateral dorsal spinal cord of SNL rats at
POD 10 after surgery. However, SNL-induced pJNK expression was
suppressed by intraperitoneal administration of TIIAS in a dose-
dependent manner. Asterisk, number sign, or ampersand each indicates
statistically significant difference (P< 0.05) between groups, n= 4 for
each group. SNL, spinal nerve ligation; TIIAS, tanshinone IIA sulfonate;
Veh, vehicle; JNK, c-Jun N-terminal kinase.
Tang et al. Journal of Neuroinflammation  (2015) 12:57 Page 8 of 12these three pro-inflammatory cytokines to varying de-
grees (P < 0.05, compared with the SNL-vehicle group,
respectively). Clear differences were observed between
the groups with two different dosages (10 and 50 mg/
kg) (P < 0.05, respectively). Similar results were ob-
tained regarding the role of TIIAS on MCP-1 expression.
The low dosage of TIIAS (2 mg/kg) did not have any obvi-
ous effect on MCP-1 expression, while higher dosages of
TIIAS (10 and 50 mg/kg) resulted in the decrease of
MCP-1 (P < 0.05, compared with the SNL-vehicle group;
Figure 6B). These results suggest that intraperitoneal TIIAS
can effectively inhibit SNL-induced up-regulation of pro-
inflammatory cytokines and MCP-1 in a dose-dependent
manner.Analgesic effect of TIIAS via the inhibition of JNK
activation in astrocytes after SNL
To further verify whether the analgesic effects of TIIAS
was occurring through the inhibition of JNK activation in
astrocytes after SNL, SP600125 (a specific JNK inhibitor),
was delivered intrathecally into the L4/5 spinal cord. Intra-
thecal administration of SP600125 (5 μg) significantly
increased the mechanical PWT compared with the vehicle
control (P < 0.05; Figure 7A). Furthermore, co-treatment
with TIIAS and SP600125 did not lead to significant
increases in mechanical PWT compared with the
TIIAS-alone group (P > 0.05; Figure 7A). Additionally,
co-treatment with TIIAS and SP600125 did not result
in further inhibition of MCP-1 compared with the
TIIAS-alone group (P > 0.05; Figure 7B). Thus, the
analgesic effect of TIIAS appeared to rely mainly on
the inhibition of JNK activation.
Discussion
In the present study, behavioral testing demonstrated that
administration of TIIAS alleviated the mechanical allody-
nia and thermal hypersensitivity of NP rats. Additionally,
the activation of astrocytes and the JNK pathway was
markedly inhibited, and the production of pro-
inflammatory cytokines was also suppressed. We also
demonstrated that the anti-nociception effect of TIIAS
and JNK inhibitor (SP600125) co-administration on
mechanical allodynia was not altered compared with
TIIAS administration alone. Furthermore, the expres-
sion of MCP-1, which is known to be the downstream
chemokine of MAPK pathway, was significantly attenu-
ated by TIIAS administration. Taken together, our
results indicate that the analgesic effect of TIIAS is
likely mediated wholly or in a large part by inhibiting
the activation of JNK/MCP-1 pathway in activated
astrocytes after SNL injury.
SNL is a widely used experimental model to stimulate
the major events of NP in the rat. In this model, the uni-
lateral L5 spinal nerve was tightly ligated, which results
in primary damage of the nerve [26]. This initiates a cas-
cade of inflammatory reactions in the spinal cord, and
NP becomes evident. A previous study observed that the
mechanical allodynia began to be measureable the third
day after SNL and was maintained until the 30th day
after primary damage [27]. Danshen, a traditional Chinese
drug, has been used in treating several kinds of diseases
in China [28]. Tanshinone IIA is one of the major
active components of Danshen. Recent studies have re-
ported that TIIAS has potent anti-inflammatory effects
[19,29,30]. In the present study, mechanical allodynia
began to be obvious from POD 3 after SNL injury, and
TIIAS administration significantly alleviated mechan-
ical allodynia from POD 5 to POD 10, indicating that
TIIAS may be a beneficial agent for treating NP.
Figure 6 Effects of intraperitoneal injection of TIIAS on SNL-induced pro-inflammatory cytokines and monocyte chemotactic protein
(MCP-1) level in spinal dorsal horn revealed by ELISA. The levels of IL-1β, IL-6, and TNF-α were increased 10 days after SNL injury in the ipsilateral
spinal dorsal horn (A1-A3, B). The lowest dosage (2 mg/kg) of TIIAS did not have any obvious effects on the expression of IL-1β, IL-6, and MCP-1
after SNL injury. However, SNL-induced elevated IL-1β, IL-6, and MCP-1 expression was reduced by the treatment of TIIAS (10 and 50 mg/kg) in a
dose-dependent manner. TIIAS (2, 10, and 50 mg/kg) could down-regulate SNL-induced elevated TNF-α in a dose-dependent manner (A1-A3, B).
Asterisk, number sign, or dollar sign each indicates statistically significant difference (P < 0.05) between groups, n = 4 for each group. SNL, spinal
nerve ligation; TIIAS, tanshinone IIA sulfonate; Veh, vehicle; IL-1β, interleukin-1 beta.
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spinal dorsal horn was also down-regulated. Astrocytes
play a pivotal role in the introduction and maintenance
of NP, acting as the main immune cells in the central
nervous system. After the nerve injury, the activation of
spinal astrocytes persisted until the 150th day, which
was regarded as a main event of the NP-related inflam-
matory reaction in the spinal dorsal horn [22,31,32]. Re-
cent studies found that L-alpha-aminoadipate, a specific
inhibitor of astrocytes, produces dose-dependent inhib-
ition of nerve injury-induced mechanical allodynia
[33,34]. In the present study, we also observed the
alleviation of mechanical allodynia after the application
of TIIAS. Meanwhile, down-regulation of GFAP expres-
sion in the spinal dorsal horn was observed, indicating
that astrocytic activation was suppressed. These results
indicated that the anti-nociceptive effect of TIIAS maypossibly be related with the suppression of astrocytic
activation.
JNK, a key member of the MAPK pathway, plays an
important role in astrocytic activation after peripheral
nerve injury [35-37]. The phosphorylated JNK (active
form) is increased after SNL, which has been shown to
have a critical role in intracellular signal transduction.
And intrathecal application of SP600125, a JNK selective
inhibitor, either before or after SNL, can increase the
mechanical PWT significantly [33,38]. Another JNK
inhibitor, D-JNKI-1, also showed potent anti-nociceptive
effects on SNL-induced NP [33]. In the present study,
SNL-induced increases of pJNK were almost totally
blocked by the intrathecal injection of TIIAS, accompan-
ied by the alleviation of tactile allodynia. Furthermore,
co-treatment with TIIAS and SP600125 did not result in
significant increases in mechanical PWT compared with
Figure 7 Analgesic effects and MCP-1 expression with
co-treatment of TIIAS and SP600125 in SNL rats. SP600125, a
specific JNK inhibitor, was injected intrathecally at POD 3 to POD 10
(n = 12 for each group). Intrathecal administration of SP600125
significantly increased the mechanical PWT compared with the
vehicle control, and co-treatment with TIIAS and SP600125 did not
lead to more significant increases in mechanical PWT compared with
the TIIAS-alone group (A). And also, co-treatment with TIIAS and
SP600125 did not result in further inhibition of MCP-1 compared
with TIIAS-alone group (B). Data (A) are presented as mean ± SEM
(*P < 0.05, n = 12, vs vehicle group, repeated measures ANOVA). Data
(B) are presented as mean ± SD (*P< 0.05, vs SNL-vehicle group, n = 4).
SNL, spinal nerve ligation; TIIAS, tanshinone IIA sulfonate; Veh, vehicle;
MCP-1, monocyte chemoattractant protein-1; SP, sodium pyruvate.
Figure 8 Schematic illustrating potential mechanisms of the
anti-nociceptive effects induced by TIIAS on neuropathic pain.
Peripheral nerve injury (like spinal nerve ligation) increases pro-
inflammatory cytokines and induces glial activation in the spinal dorsal
horn (A). The potential roles of TIIAS in spinal pain transmission are
presented in (B). Peripheral nerve injury induces pro-inflammatory
cytokines, causing the activation of spinal JNK pathway in astrocytes.
The up-regulation of MCP-1 produced by astrocytes via JNK-mediated
pathway after SNL may facilitate the glutamate-related synaptic
transmission and enhance neuropathic pain. JNK activation could
be the targeting sites of TIIAS. Down-regulation of JNK/MCP-1 may
be involved in the anti-nociceptive effect of TIIAS on neuropathic
pain. TIIAS, tanshinone IIA sulfonate; JNK, c-Jun N-terminal kinase;
MCP-1, monocyte chemoattractant protein-1.
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indicated that inhibition of JNK in the spinal dorsal horn
of SNL rats was consistent with the analgesic effect of
TIIAS. Recent studies have indicated that in some
pathological processes, activation of JNK can be inhib-
ited by TIIAS, especially in the signal transduction of
anti-inflammatory and anti-apoptotic pathways [39-42].
The pro-inflammatory cytokines, especially TNF-α and
IL-1β, induced by peripheral nerve injury, are essential
triggers for the activation of JNK in spinal astrocytes
underlying the development of neuropathic pain. In our
study, TIIAS administration also decreased theexpression of the three pro-inflammatory cytokines
(TNF-α, IL-6, and IL-1β), indicating that the inhibition
of the activation of JNK via the suppression of the inflam-
matory cascade is correlated with the analgesic effect of
TIIAS.
Accumulating evidence indicates that MCP-1 is pro-
duced by astrocytes via the JNK-mediated pathway after
SNL and mediates pain via CCR2 receptors [13,43,44].
Treatment with a JNK inhibitor inhibits production of
MCP-1 in IL-1β- or TNF-α-stimulated cultured astro-
cytes [13,45]. Another study found that propentofylline,
an anti-allodynic agent, dampens MCP-1 release from
astrocytes [46]. Additionally, mice overexpressing MCP-1
in astrocytes display enhanced nociceptive responses
[47]. As for the involvement of MCP-1 in central
sensitization, it was also reported that MCP-1 increases
pain sensitivity via direct activation of NMDA receptors
in dorsal horn neurons [13]. In this study, the analgesic
effects of TIIAS were mediated in part by the down-
Tang et al. Journal of Neuroinflammation  (2015) 12:57 Page 11 of 12regulation of MCP-1. Increased MCP-1 expression was
also reported in DRG neurons after nerve injury [48].
However, in the spinal cord, MCP-1 is predominantly
expressed in spinal astrocytes after SNL [13]. In our
study, the change of MCP-1 expression in SNL model
after TIIAS administration was regarded in the spinal
astrocytes.
Conclusions
In the present study, we showed that TIIAS had a potent
analgesic effect on SNL-induced NP. Our results also indi-
cated that the analgesic effect of TIIAS coincides with the
inhibition of the inflammatory reactions in the spinal dor-
sal horn. Furthermore, the suppression of astrocyte-
related JNK phosphorylation and MCP-1 was involved in
the analgesic effect of TIIAS (Figure 8). These findings in
the present study provide evidence for understanding the
mechanisms underlying the anti-nociception effects of
TIIAS in a SNL-induced neuropathic pain model and
support a novel strategy for treating peripheral nerve
injury-induced neuropathic pain.
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